0001209191-17-053691.txt : 20170922
0001209191-17-053691.hdr.sgml : 20170922
20170922160442
ACCESSION NUMBER: 0001209191-17-053691
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170920
FILED AS OF DATE: 20170922
DATE AS OF CHANGE: 20170922
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: RINGO WILLIAM R
CENTRAL INDEX KEY: 0001238325
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30171
FILM NUMBER: 171097698
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC
CENTRAL INDEX KEY: 0001001233
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 680359556
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 501 CANAL BLVD
STREET 2: POINT RICHMOND TECH CNTR.
CITY: RICHMOND
STATE: CA
ZIP: 94804
BUSINESS PHONE: 5109706000
MAIL ADDRESS:
STREET 1: 501 CANAL BLVD
STREET 2: POINT RICHMOND TECH CNTR.
CITY: RICHMOND
STATE: CA
ZIP: 94804
FORMER COMPANY:
FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC
DATE OF NAME CHANGE: 20000208
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-09-20
0
0001001233
SANGAMO THERAPEUTICS, INC
SGMO
0001238325
RINGO WILLIAM R
C/O SANGAMO THERAPEUTICS, INC.
POINT RICHMOND TECH CTR, 501 CANAL BLVD.
RICHMOND
CA
94804
1
0
0
0
Common Stock
2017-09-20
4
M
0
31000
6.05
A
31800
D
Common Stock
2017-09-20
4
S
0
31000
14.3741
D
800
D
Stock Option (Right to Buy)
6.05
2017-09-20
4
M
0
31000
0.00
D
2020-04-15
Common Stock
31000
0
D
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.25 to $14.55, inclusive. The Reporting Person undertakes to provide to Sangamo Therapeutics, Inc., any security holder of Sangamo Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
The shares underlying the stock option are fully vested and exercisable.
/s/ Florence Tam, Attorney-in-Fact
2017-09-22